Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug
Khokon Miah Akanda, Senior Brand Executive at Apex Pharma Limited, shared on LinkedIn:
“FDA approves a first-in-class hypertension drug!
The US FDA has recently approved Baxfendy (baxdrostat) by AstraZeneca, the first-ever aldosterone synthase inhibitor for hypertension treatment.
What makes this approval significant is its completely new mechanism of action. Instead of only managing symptoms, the drug directly targets aldosterone production, a hormone linked to persistently high blood pressure and cardiovascular risk.
In Phase III trials, the drug demonstrated clinically meaningful reductions in systolic blood pressure in patients whose hypertension remained uncontrolled despite multiple medications.
This marks one of the most important cardiovascular drug innovations in recent years and highlights how pharma continues to evolve toward more targeted and mechanism-based therapies.
Exciting to see innovation reshaping chronic disease management.”
Stay updated with Hemostasis Today.
-
May 30, 2026, 18:11Alessandro Perrella: It is Not Only about “How High the CRP is”, but “in Which Patient” We are Measuring That Value
-
May 30, 2026, 18:11Jasper van Grunsven: Grateful for Our Rare Disease Team and the Commitment That Drives Our Mission
-
May 30, 2026, 18:10Open Registration for the 2026 Thrombosis Canada Annual Education Conference – Thrombosis Canada
-
May 30, 2026, 18:09Peter Zdziarski: Approval Does Not Mean NovoSeven is 100% Effective or Risk-Free in GT
-
May 30, 2026, 17:07Deepak Yadav: A Privilege to Talk on ESUS at CREST Stroke Conclave 2026
-
May 30, 2026, 16:59Syed A Rizvi: Medical Scoring Systems – Small Numbers, Big Clinical Decisions
-
May 30, 2026, 16:53Timothy “Tim” Sheehan: BNY Wealth Joins the Fight Against Blood Disorders In Support of Hemophilia of Georgia
-
May 30, 2026, 16:51Nouf Bahri: Anticoagulation Initiation for New-Onset Atrial Fibrillation in Critical Illness
-
May 30, 2026, 16:47Mohammed Al Rubaei: Where Do I Start When Evaluating a Patient With Suspected Hemolysis?